ImmunityBio Secures \$100M Financing and Marks Global Expansion Milestones

Key Highlights

• \$75 Million Non-Dilutive Financing: ImmunityBio, Inc. (NASDAQ: IBRX) has secured \$75 million in non-dilutive funding under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital. This brings the total committed capital from Oberland to \$375 million.
• Debt Reduction via Equity Conversion: Simultaneously, Nant Capital, LLC—an entity affiliated with ImmunityBio’s Executive Chairman—has converted \$25 million of outstanding promissory notes into 4.6 million shares of common stock, reducing the company’s debt and strengthening its balance sheet.
• Global Expansion Supported by Financing: The proceeds from these transactions will support ImmunityBio’s global expansion following recent regulatory approvals and will advance the company’s broader immunotherapy pipeline.
• Regulatory Approvals Across 34 Countries: ImmunityBio’s key asset, ANKTIVA® (nogapendekin alfa inbakicept-pmln), is now approved or authorized for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) across five major regulatory jurisdictions, covering approximately 34 countries. Approvals include the United States (FDA), United Kingdom (MHRA), Kingdom of Saudi Arabia (SFDA), European Union (European Commission), and Macau SAR.
• First Global Approval for Lung Cancer: Saudi Arabia has granted conditional accelerated approval for ANKTIVA in metastatic non-small cell lung cancer (NSCLC) in combination with checkpoint inhibitors, marking the first jurisdiction to authorize ANKTIVA for lung cancer.
• Rapid International Expansion: The global regulatory footprint was established in under two years from initial U.S. FDA approval in April 2024, highlighting aggressive international growth.

Detailed Analysis

Strategic Financing Moves

ImmunityBio’s announcement of \$100 million in financing transactions is a significant event for shareholders and investors. The \$75 million non-dilutive funding from Oberland Capital boosts liquidity without diluting existing equity holders, a positive for share value. The amended RIPA carries only a modest increase in royalty payback rate, with the royalty cap maintained, ensuring manageable future obligations. Additionally, the conversion of \$25 million in debt to equity by Nant Capital demonstrates strong insider confidence and reduces financial leverage, further solidifying the company’s balance sheet.

Global Regulatory Approvals and Commercial Expansion

ANKTIVA® is now commercially available or authorized in 34 countries. The asset is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, designed to activate NK and memory T cells to deliver durable cancer responses. Regulatory approvals span key markets:

• United States: FDA approval for BCG-unresponsive NMIBC CIS (April 2024)
• United Kingdom: MHRA authorization (July 2025 inferred)
• Saudi Arabia: SFDA accelerated approval for BCG-unresponsive NMIBC CIS (January 2026) and conditional approval for NSCLC (January 2026)
• European Union: Conditional marketing authorization covering 27 EU member states plus Iceland, Norway, and Liechtenstein (February 2026)
• Macau SAR: Pharmaceutical Administration Bureau authorization (March 2026)

The rapid establishment of a global footprint in less than two years is a testament to ImmunityBio’s execution and market potential. The first global authorization for lung cancer in Saudi Arabia could open new commercial avenues, making this news highly price-sensitive.

Pipeline and Platform Overview

ImmunityBio’s Cancer BioShield™ platform, anchored by ANKTIVA®, is complemented by adenovirus-vectored vaccines, allogeneic and autologous NK-cell therapies, and additional immunomodulators. The platform aims to activate crucial immune cells and generate lasting immunological memory, potentially reducing reliance on high-dose chemo-radiation therapy and supporting durable immune responses.

Forward-Looking Statements and Risks

Investors should note that ImmunityBio’s forward-looking statements are subject to significant risks, including clinical trial outcomes, regulatory processes, manufacturing capabilities, product supply issues (such as ongoing BCG shortages), competitive dynamics, reimbursement, and intellectual property protection. These risks are detailed in their SEC filings.

Shareholder Implications

• Non-dilutive financing and debt reduction: These moves improve financial health without diluting shareholders, which is generally positive for share price.
• Rapid regulatory expansion: The pace and breadth of ANKTIVA® approvals suggest strong commercial momentum and growth prospects.
• New indications: First approval for lung cancer in Saudi Arabia could position ImmunityBio as a leader in this space, potentially attracting investor interest.
• Insider confidence: Debt conversion by Nant Capital underscores belief in the company’s future.
• Risks: Clinical, regulatory, manufacturing, and market risks remain and could affect share value.

Contact Information

Investors: Hemanth Ramaprakash, PhD, MBA – +1 858-746-9289, [email protected]
Media: Sarah Singleton – +1 415-290-8045, [email protected]

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information herein is based on ImmunityBio’s press release and public filings. Investors should consult official SEC filings and their financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

View ImmunityBio, Inc. Historical chart here